Protein engineering to target complement evasion in cancer.
about
Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.Preclinical safety, pharmacokinetics, pharmacodynamics, and biodistribution studies with Ad35K++ protein: a novel rituximab cotherapeutic.Polymersomes and their applications in cancer delivery and therapy.Recombinant Ad35 adenoviral proteins as potent modulators of human T cell activation.
P2860
Protein engineering to target complement evasion in cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Protein engineering to target complement evasion in cancer.
@en
type
label
Protein engineering to target complement evasion in cancer.
@en
prefLabel
Protein engineering to target complement evasion in cancer.
@en
P2860
P1433
P1476
Protein engineering to target complement evasion in cancer.
@en
P2093
André Lieber
P2860
P304
P356
10.1016/J.FEBSLET.2013.11.007
P407
P577
2013-11-14T00:00:00Z